Characterization of patients with musculoskeletal injuries treated with platelet-rich plasma, Quetzaltenango, Guatemala
Vol. 161 No. 3: July - September, 2022
Original Articles
May 3, 2022
September 15, 2022
Background: platelet-rich plasma (PRP) is an emerging autologous cell therapy with great potential for various treatment plans in regenerative medicine. Worldwide, tissue repair strategies are needed in musculoskeletal (M
1.
Cifuentes-Sosa A, Estrada-Taracena M, López-Samayoa B, Vásquez-Cifuentes AM, Gutiérrez-Herrera E, Mérida-Díaz L, et al. Characterization of patients with musculoskeletal injuries treated with platelet-rich plasma, Quetzaltenango, Guatemala. Rev. méd. (Col. Méd. Cir. Guatem.) [Internet]. 2022 Sep. 15 [cited 2025 Jan. 6];161(3):244-9. Available from: https://stage.revistamedicagt.org/index.php/RevMedGuatemala/article/view/499
Downloads
Download data is not yet available.
Copyright (c) 2022 Ariadna Cifuentes-Sosa, Manuel Estrada-Taracena, Bernardo López-Samayoa, Angela Mariana Vásquez-Cifuentes, Edith Gutiérrez-Herrera, Luz Mérida-Díaz, Sucely Mendoza-Ordóñez, Marta Toj-Toj
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 |
This work is licensed under Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
| Copyright notice |
 |
Authors will retain their copyright and assign to the journal the right of first publication of their work, which will be simultaneously subject to a Creative Commons Attribution-Noncommercial-ShareAlike 4.0 International license (CC BY-NC-SA 4.0) that allows third parties to share the work as long as its author and its first publication in this magazine are indicated. |
|
Authors may adopt other non-exclusive license agreements for the distribution of the version of the published work (eg: deposit it in an institutional repository or publish it in a monographic volume) provided that the initial publication in this journal is indicated. |
|
Authors are allowed and recommended to disseminate their work through the internet (eg, in institutional telematic files or on their website) before and during the submission process, which can lead to interesting exchanges and increase citations of the published work. (See The effect of open access). |
| About the Creative Commons license |
|
|
You are free to: |
|
Share — copy and redistribute the material in any medium or format. |
|
Adapt — remix, transform, and build upon the material. |
|
The licensor cannot revoke these freedoms as long as you follow the license terms. |
Under the following terms: |
 |
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. |
 |
NonCommercial — You may not use the material for commercial purposes. |
 |
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. |
| No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. |
